Search
for
Sort by
Research 931–960 of 1000+
- S4890 Infliximab-Induced Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis Syndrome
- The Good and Bad News About New Drugs for Treating Alopecia Areata
- Subject Index
- 0441 Systemic autoimmune comorbidity in alopecia totalis and universalis compared with patchy alopecia areata: A retrospective cohort study
- Is the severity of alopecia areata associated with arterial stiffness?
- Interleukin-10-deficient Mice Are Less Susceptible to the Induction of Alopecia Areata
- Alopecia universalis following interferon alfa-2b and ribavirin treatment for hepatitis C.
- General practitioners’ knowledge and practices related to alopecia areata in Qassim region, Saudi Arabia
- Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
- Alterazioni dei capelli da farmaci
- Abstracts from the 2025 WDS Forum
- SARGRAMOSTIN
- Detection of hair-microRNAs as the novel potent biomarker: Evaluation of the usefulness for the diagnosis of scleroderma
- Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- New developing multiple sclerosis in a patient using tofacitinib due to alopesia areata
- Epidemiology, management and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: protocol for an observational study series
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Not just thinning: A case of alopecia universalis after mild COVID-19
- Alopecia areata as a complication of hair restoration surgery
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- A Systematic Scoping Review and Conceptual Analysis of New-Onset Fibromyalgia Manifestations After Non-Hospitalized COVID-19: Empirics, Definitions, Methodologies, Pathophysiology, Mapping of Literature, and Knowledge Gaps
- Oral Tofacitinib in Refractory Pediatric Alopecia Areata
- Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report